Filtered By:
Condition: Polycystic Ovary Syndrome
Drug: Insulin
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1112 results found since Jan 2013.
Are menstrual disorders in adolescent girls related to metabolic disorders?
CONCLUSIONS: Adolescent girls with menstrual disorders are insulin resistant, regardless of PCOS diagnosis. The severity of menstrual disorders may be related to the incidence of lipid disorders in adolescent girls.PMID:37728458 | PMC:PMC10411084 | DOI:10.5114/pedm.2023.125364
Source: Pediatric Endocrinology, Diabetes, and Metabolism - September 20, 2023 Category: Endocrinology Authors: El żbieta Foryś Adrianna Baran Aleksandra Dziurdzia Ewelina Jarosz-W ójcik Pawe ł Matusik Aneta Gawlik Ryszard Tomaszewski Agnieszka Zachurzok Source Type: research
The role of macrophages in polycystic ovarian syndrome and its typical pathological features: A narrative review
Biomed Pharmacother. 2023 Sep 14;167:115470. doi: 10.1016/j.biopha.2023.115470. Online ahead of print.ABSTRACTPolycystic ovarian syndrome (PCOS) is the most common endocrine and metabolic disorder in women of childbearing age, with ovulatory dysfunction, hyperandrogenism, and polycystic ovarian morphology (PCOM) as the clinical features. Androgen excess, insulin resistance, obesity, adipose tissue dysfunction, ovulatory dysfunction, and gut microbiota dysbiosis are the main pathological features and pathogenesis of PCOS and are related to systemic chronic low-grade inflammation and chronic ovarian tissue inflammation in PC...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - September 16, 2023 Category: Drugs & Pharmacology Authors: Yuanyuan Feng Zhijing Tang Wei Zhang Source Type: research
SPIOMET4HEALTH —efficacy, tolerability and safety of lifestyle intervention plus a fixed dose combination of spironolactone, pioglitazone and metformin (SPIOMET) for adolescent girls and young women with polycystic ovary syndrome: study protocol for a multicentre, randomised, double-blind, placebo-controlled, fo ur-arm, parallel-group, phase II clinical trial
DiscussionThe present study will be the first to evaluate —in a randomised, double-blind, placebo-controlled way—the efficacy, tolerability and safety of SPIOMET treatment for early PCOS, on top of a lifestyle intervention.Trial registrationEudraCT 2021 –003177-58. Registered on 22 December 2021.https://www.clinicaltrialsregister.eu/ctr-search/search?query=%092021-003177-58.
Source: Trials - September 15, 2023 Category: Research Source Type: clinical trials
Interleukin-38 and insulin resistance
We present that IL-38 associated signaling can be a potential target for the treatment of insulin resistance and associated diseases.PMID:37702180 | DOI:10.2174/1871530323666230911114150
Source: Endocrine, Metabolic and Immune Disorders Drug Targets - September 13, 2023 Category: Endocrinology Authors: Kamil Klejbuk Marek Str ączkowski Source Type: research
Defective uterine spiral artery remodelling and placental senescence in a pregnant rat model of polycystic ovary syndrome
This study verified previous work in which exposure to 5-dihydrotestosterone (DHT) and insulin (INS) in rats during pregnancy resulted in hyperandrogenism, insulin intolerance, and higher foetal mortality. It also found that exposure to DHT and INS dysregulated the expression of angiogenesis-related genes in the uterus and placenta. It also decreased expression of endothelial nitric oxide synthase and matrix metallopeptidases 2 and 9, increased fibrotic collagen deposits in the uterus, and reduced expression of marker genes for SpA-associated trophoblast giant cells. These changes were related to a greater proportion of un...
Source: Am J Pathol - September 9, 2023 Category: Pathology Authors: Min Hu Yuehui Zhang Xu Zhang XiuYing Zhang Xinyue Huang Yaxing Lu Yijia Li Mats Br ännström Amanda Nancy Sferruzzi-Perri Linus R Shao H åkan Billig Source Type: research
Questioning PCOS phenotypes for reclassification and tailored therapy
Trends Endocrinol Metab. 2023 Sep 1:S1043-2760(23)00158-3. doi: 10.1016/j.tem.2023.08.005. Online ahead of print.ABSTRACTPrecise diagnoses are essential for defining appropriate treatments. This is particularly true for polycystic ovary syndrome (PCOS), whose phenotypical manifestations have recently suggested a possible diversity of etiological factors. PCOS is defined on the basis of gynecological and endocrinological alterations, but the patients often display considerable metabolic impairments, such as insulin resistance, that may worsen typical symptoms. The Rotterdam criteria fail to address this aspect, and the medi...
Source: Trends in Endocrinology and Metabolism: TEM - September 4, 2023 Category: Endocrinology Authors: Samuel Harry Myers Michele Russo Simona Dinicola Gianpiero Forte Vittorio Unfer Source Type: research
